Antimicrobial Resistance Project BioShield: BARDA Antibiotic for AMR and Biothreat Pathogens
Closed Solicitation Posted
- Solicitation number
- 75A50122R00009
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Responses due
- Set-aside
- Total Small Business
Opportunity facts
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Notice details come from SAM.gov. Updated .
About this opportunity
The Office of the Biomedical Advanced Research and Development Authority within the Department of Health and Human Services seeks to procure through an acquisition vehicle the late-stage development of an antibiotic product for treatment and/or post-exposure prophylaxis of one or more biothreat pathogens, including Yersinia pestis, Francisella tularensis, or Burkholderia pseudomallei. The product must have received FDA approval within the last 10 years or be in Phase 3 clinical development. Proposals are due by April 6, 2022 as specified in Request for Proposal number 75A50122R00009. The anticipated contract includes completion of regulatory requirements and post-marketing commitments to support procurement of up to 10,000 treatment or PEP courses for delivery to the Strategic National Stockpile or vendor-managed inventory.
This total small business set-aside opportunity falls under NAICS code 541715 and PSC code R425. The anticipated contract value ranges from $20-100M to support delivery of up to 10,000 treatment courses over five years. Performance will take place within the contiguous United States. An amendment to the RFP extends the response deadline.
Notice text
2 versions
Update #2 · Latest ·
RFP # 75A50122R00009 _Amendment 01
The purpose of this Amendment is to make the following changes to the solicitation:
1) Update Article L.7. to reflect a new cutoff date for questions. (New cutoff date for questions is February 24, 2022 at 12 PM ET)
2) Update subarticle I.3.2. to add FAR 52.219-14 in full text.
3) Update subarticle L.5.3. to remove the Protection of Human Subjects as a required form in the BUSINESS proposal. Note: This remains a requirement in the TECHNICAL proposal.
4) Update Article M.3. to remove U.S. based manufacturing as a mandatory evaluation criterion. Note: Language concerning U.S. based manufacturing remains in the Statement of Objectives and Article M.4. - Technical Evaluation Criteria.
5) Update Section J to add Attachment 19 (Responses to Inquiries-February 10,2022). Note: This attachment contains responses to all inquiries that may be necessary for the preparation of proposals.
Please see the attached Amendment for a conformed copy of the solicitation.
Update #1 ·
The Office of the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) intends to use an acquisition to procure, stockpile, and invest in the late-stage development of an antibiotic product for commercial use for treatment and/or post-exposure prophylaxis (PEP) of one or more biothreat indications.
Please see attached Request for Proposal 75A50122R00009 for a detailed description of the requirement.
Files
| File | Type | Posted |
|---|---|---|
| 75A50122R00009_Amendment 01.pdf | ||
| 75A50122R00009.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Solicitation | |
| Antimicrobial Resistance Project BioShield: BARDA Antibiotic for AMR and Biothreat Pathogens | Pre-Solicitation |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity